Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): Emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections

Diagnostic Microbiology and Infectious Disease

Volumn 43, Issue 1, 2002, Pages 49-60

  Johnson, David M ^a   Biedenbach, Douglas J ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTAZIDIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TETRACYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMMUNICABLE DISEASE; CONTROLLED STUDY; DRUG POTENCY; ENZYME SYNTHESIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT INFECTION;

COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; EUROPE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; LATIN AMERICA; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA; PENICILLANIC ACID; PIPERACILLIN; RESPIRATORY TRACT INFECTIONS; SENTINEL SURVEILLANCE; TIME FACTORS;

EID: 0036273689     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(02)00358-9     Document Type: Article

References (40)

1. National survey of the in vitro spectrum of piperacillin/tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers
2. Susceptibility of Haemophilus influenzae to piperacillin/tazobactam combinations: Interpretive criteria and quality control limits for standardized tests
3. Randomized, double-blind, comparison efficacy study of piperacillin/tazobactam (PTZ) and imipenem/cilastatin (IPM) administered intravenously q8h to treat intra-abdominal infections (IAI)
4. Piperacillin/tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections
5. Treatment of ventilator-associated pneumonia with piperacillin/tazobactam/amikacin versus ceftazidime/amikacin: A multicenter, randomized controlled trial
6. Comparative activities of piperacillin and tazobactam against clinical isolates of Legionella spp
7. Piperacillin/tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
8. In vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates
9. A multicenter, double-blind, placebo-controlled trial comparing piperacillin/tazobactam with and without amikacin as empiric therapy for febrile neutropenia
10. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections
11. A randomized comparison of piperacillin/tazobactam versus ceftriaxone and gentamicin in 172 severely neutropenic patients with hematologic malignancies
12. World-wide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999
13. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
14. Prospective randomized comparison of imipenem-cilastatin and piperacillin/tazobactam in nosocomial pneumonia or peritonitis
15. Beta-lactamase production by enteric bacilli
16. Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: Significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999)
17. Piperacillin/tazobactam (YTR 830) combination comparative antimicrobial activity against 5,889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains
18. Prediction of piperacillin/tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa and other bacteria using ticarcillin/clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results
19. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group
20. Clinical efficacy and cost effectiveness of piperacillin/tazobactam versus ampicillin + gentamicin + metronidazole in the treatment of intra-abdominal infections
21. Antimicrobial susceptibility of blood culture isolates of viridans streptococci: Relationship to a change in empirical antibiotic therapy in febrile neutropenia
22. Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin/tazobactam
23. Safety profile of piperacillin/tazobactam in phase I and III clinical studies
24. Comparative antimicrobial activity of piperacillin/tazobactam tested against more than 5,000 recent clinical isolates from five medical centers. A re-evaluation after five years
25. In vitro activity of piperacillin/tazobactam versus other broad-spectrum antibiotics against nosocomial Gram-negative pathogens isolated from burn patients
26. Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections
27. Multicenter evaluation of the in vitro activity of piperacillin/tazobactam compared with eleven selected β-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic Gram-positive and Gram-negative bacteria
28. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections
29. Piperacillin/tazobactam: An updated review of its use in the treatment of bacterial infections
30. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: Resistance implications in the treatment of serious infections
31. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infections
32. Role of piperacillin/tazobactam in the treatment of infections caused by β-lactamase-producing pathogens
33. Cefepime plus amikacin versus piperacillin/tazobactam plus amikacin for initial antibiotic therapy in hematological patients with febrile neutropenia: Results of an open, randomized, multicenter trial
34. Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia
35. Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection
36. Treatment of hospitalized patients with complicated skin and skin structure infections: Double-blind, randomized, multicenter study of piperacillin/tazobactam versus ticarcillin/clavulanate
37. Therapy of soft tissue infections with piperacillin/tazobactam
38. The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia